|
FDA speeds pharmaceutical product reviews. (Pharmaceutical).(US Food and Drug Administration)(Brief Article)
From:
R & D
| Date:
October 1, 2002
| COPYRIGHT 2002 Reed Business Information. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.Copyright information
|
The US Food and Drug Administration (FDA) has announced a consolidation of responsibilities for reviewing new pharmaceutical products. Drug and biological product reviews have been conducted in part by the FDA's Center for Biologics Evaluation and Research (CBER) and also by its Center for Drug Evaluation and Research (CDER). Henceforth, CDER will be responsible for the reviews.
According to the agency, the consolidation will let CBER concentrate its expertise on the are...
Related newspaper, magazine, and journal articles from HighBeam Research
|
Concerns With Drug Approval Slowdown.(Brief Article)(Statistical Data Included)
Chemical Market Reporter
; THE PHARMACEUTICAL industry is expressing concern about ... increase in the amount of time it took the Food and Drug Administration (FDA) last year to approve prescription drugs ... streak of quicker approval times, the FDA in 2000 approved 27 new drugs in an ... 1999. The length of time it ...
|
